| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.
|
Alzheimers Dement
|
2011
|
24.26
|
|
2
|
Clinical and biomarker changes in dominantly inherited Alzheimer's disease.
|
N Engl J Med
|
2012
|
14.14
|
|
3
|
Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory.
|
J Neurosci
|
2005
|
12.85
|
|
4
|
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.
|
Ann Neurol
|
2006
|
11.23
|
|
5
|
11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment.
|
Brain
|
2008
|
9.64
|
|
6
|
Frequent amyloid deposition without significant cognitive impairment among the elderly.
|
Arch Neurol
|
2008
|
7.95
|
|
7
|
Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease.
|
Brain
|
2007
|
6.39
|
|
8
|
Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B.
|
J Cereb Blood Flow Metab
|
2005
|
6.25
|
|
9
|
Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease.
|
Brain
|
2008
|
5.89
|
|
10
|
Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease.
|
Proc Natl Acad Sci U S A
|
2009
|
5.55
|
|
11
|
Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents.
|
J Med Chem
|
2003
|
5.34
|
|
12
|
Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis.
|
J Nucl Med
|
2005
|
5.10
|
|
13
|
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.
|
Lancet Neurol
|
2010
|
5.03
|
|
14
|
Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease.
|
Ann Neurol
|
2011
|
4.38
|
|
15
|
Imaging of amyloid burden and distribution in cerebral amyloid angiopathy.
|
Ann Neurol
|
2007
|
4.11
|
|
16
|
Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report.
|
Arch Neurol
|
2007
|
3.83
|
|
17
|
The long-term effects of conventional and atypical antipsychotics in patients with probable Alzheimer's disease.
|
Am J Psychiatry
|
2013
|
3.06
|
|
18
|
The role of biomarkers in clinical trials for Alzheimer disease.
|
Alzheimer Dis Assoc Disord
|
2006
|
2.86
|
|
19
|
Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab.
|
Arch Neurol
|
2011
|
2.75
|
|
20
|
Amyloid imaging in mild cognitive impairment subtypes.
|
Ann Neurol
|
2009
|
2.66
|
|
21
|
Dynamics of the microglial/amyloid interaction indicate a role in plaque maintenance.
|
J Neurosci
|
2008
|
2.57
|
|
22
|
Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report.
|
Arch Neurol
|
2009
|
2.42
|
|
23
|
Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-beta ligand in transgenic mice.
|
Proc Natl Acad Sci U S A
|
2003
|
2.13
|
|
24
|
Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice.
|
J Clin Invest
|
2005
|
1.94
|
|
25
|
Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network.
|
Clin Investig (Lond)
|
2012
|
1.90
|
|
26
|
Basal cerebral metabolism may modulate the cognitive effects of Abeta in mild cognitive impairment: an example of brain reserve.
|
J Neurosci
|
2009
|
1.89
|
|
27
|
Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid.
|
Biol Psychiatry
|
2009
|
1.85
|
|
28
|
A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain.
|
Bioorg Med Chem Lett
|
2002
|
1.79
|
|
29
|
Using a reference tissue model with spatial constraint to quantify [11C]Pittsburgh compound B PET for early diagnosis of Alzheimer's disease.
|
Neuroimage
|
2007
|
1.67
|
|
30
|
Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's disease.
|
Neuroimage
|
2006
|
1.65
|
|
31
|
In vivo optical imaging of amyloid aggregates in brain: design of fluorescent markers.
|
Angew Chem Int Ed Engl
|
2005
|
1.60
|
|
32
|
Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease.
|
Neuroimage
|
2007
|
1.53
|
|
33
|
Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia.
|
Trends Neurosci
|
2011
|
1.51
|
|
34
|
Characterizing regional correlation, laterality and symmetry of amyloid deposition in mild cognitive impairment and Alzheimer's disease with Pittsburgh Compound B.
|
J Neurosci Methods
|
2008
|
1.46
|
|
35
|
In vivo fibrillar beta-amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults.
|
Arch Neurol
|
2011
|
1.40
|
|
36
|
Brain imaging in Alzheimer disease.
|
Cold Spring Harb Perspect Med
|
2012
|
1.37
|
|
37
|
Clinical severity of Alzheimer's disease is associated with PIB uptake in PET.
|
Neurobiol Aging
|
2008
|
1.31
|
|
38
|
Imaging Alzheimer pathology in late-life depression with PET and Pittsburgh Compound-B.
|
Alzheimer Dis Assoc Disord
|
2008
|
1.30
|
|
39
|
Progression of cerebral amyloid load is associated with the apolipoprotein E ε4 genotype in Alzheimer's disease.
|
Biol Psychiatry
|
2010
|
1.29
|
|
40
|
Consideration of optimal time window for Pittsburgh compound B PET summed uptake measurements.
|
J Nucl Med
|
2009
|
1.27
|
|
41
|
X-34 labeling of abnormal protein aggregates during the progression of Alzheimer's disease.
|
Methods Enzymol
|
2006
|
1.25
|
|
42
|
Longitudinal cerebral blood flow and amyloid deposition: an emerging pattern?
|
J Nucl Med
|
2008
|
1.22
|
|
43
|
Impact of amyloid imaging on drug development in Alzheimer's disease.
|
Nucl Med Biol
|
2007
|
1.19
|
|
44
|
Pulse wave velocity is associated with β-amyloid deposition in the brains of very elderly adults.
|
Neurology
|
2013
|
1.18
|
|
45
|
Imaging technology for neurodegenerative diseases: progress toward detection of specific pathologies.
|
Arch Neurol
|
2005
|
1.18
|
|
46
|
Classification of amyloid-positivity in controls: comparison of visual read and quantitative approaches.
|
Neuroimage
|
2013
|
1.17
|
|
47
|
In vivo assessment of amyloid-β deposition in nondemented very elderly subjects.
|
Ann Neurol
|
2013
|
1.17
|
|
48
|
Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study.
|
Acta Neuropathol
|
2012
|
1.16
|
|
49
|
Imaging amyloid-beta deposits in vivo.
|
J Cereb Blood Flow Metab
|
2002
|
1.15
|
|
50
|
Amyloid burden and neural function in people at risk for Alzheimer's Disease.
|
Neurobiol Aging
|
2013
|
1.14
|
|
51
|
Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease.
|
Arch Neurol
|
2009
|
1.14
|
|
52
|
Inter-rater reliability of manual and automated region-of-interest delineation for PiB PET.
|
Neuroimage
|
2010
|
1.13
|
|
53
|
Cognitive trajectories associated with β-amyloid deposition in the oldest-old without dementia.
|
Neurology
|
2013
|
1.11
|
|
54
|
Development of positron emission tomography β-amyloid plaque imaging agents.
|
Semin Nucl Med
|
2012
|
1.09
|
|
55
|
Correspondence between in vivo (11)C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques.
|
Acta Neuropathol
|
2012
|
1.09
|
|
56
|
Development of a PET/SPECT agent for amyloid imaging in Alzheimer's disease.
|
J Mol Neurosci
|
2004
|
1.08
|
|
57
|
Imaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound B.
|
Alzheimers Dement
|
2012
|
1.03
|
|
58
|
Plasma and cerebrospinal fluid alpha1-antichymotrypsin levels in Alzheimer's disease: correlation with cognitive impairment.
|
Ann Neurol
|
2003
|
1.01
|
|
59
|
Psychosis in Alzheimer disease: postmortem magnetic resonance spectroscopy evidence of excess neuronal and membrane phospholipid pathology.
|
Neurobiol Aging
|
2002
|
1.00
|
|
60
|
PK11195 labels activated microglia in Alzheimer's disease and in vivo in a mouse model using PET.
|
Neurobiol Aging
|
2008
|
1.00
|
|
61
|
Amyloid imaging in dementias with atypical presentation.
|
Alzheimers Dement
|
2012
|
0.99
|
|
62
|
Measuring target effect of proposed disease-modifying therapies in Alzheimer's disease.
|
Neurotherapeutics
|
2008
|
0.97
|
|
63
|
Lack of association between 11C-PiB and longitudinal brain atrophy in non-demented older individuals.
|
Neurobiol Aging
|
2010
|
0.96
|
|
64
|
Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta.
|
Adv Pharmacol
|
2012
|
0.94
|
|
65
|
Role of biomarkers in studies of presymptomatic Alzheimer's disease.
|
Alzheimers Dement
|
2005
|
0.94
|
|
66
|
β-Amyloid 42/40 ratio and kalirin expression in Alzheimer disease with psychosis.
|
Neurobiol Aging
|
2012
|
0.91
|
|
67
|
Targeting prion amyloid deposits in vivo.
|
J Neuropathol Exp Neurol
|
2004
|
0.91
|
|
68
|
Disclosure of amyloid imaging results to research participants: has the time come?
|
Alzheimers Dement
|
2013
|
0.91
|
|
69
|
Dendritic spine density, morphology, and fibrillar actin content surrounding amyloid-β plaques in a mouse model of amyloid-β deposition.
|
J Neuropathol Exp Neurol
|
2013
|
0.90
|
|
70
|
Synthesis and beta-amyloid binding properties of rhenium 2-phenylbenzothiazoles.
|
Bioorg Med Chem Lett
|
2009
|
0.90
|
|
71
|
Cognitive aging in persons with minimal amyloid-β and white matter hyperintensities.
|
Neuropsychologia
|
2013
|
0.88
|
|
72
|
Apolipoprotein D is a component of compact but not diffuse amyloid-beta plaques in Alzheimer's disease temporal cortex.
|
Neurobiol Dis
|
2005
|
0.88
|
|
73
|
Development and screening of contrast agents for in vivo imaging of Parkinson's disease.
|
Mol Imaging Biol
|
2013
|
0.87
|
|
74
|
Predicting positivity for a new era of Alzheimer disease prevention trials.
|
Neurology
|
2012
|
0.87
|
|
75
|
Aβ Imaging: feasible, pertinent, and vital to progress in Alzheimer's disease.
|
Eur J Nucl Med Mol Imaging
|
2012
|
0.83
|
|
76
|
Positron emission tomography radioligands for in vivo imaging of Aβ plaques.
|
J Labelled Comp Radiopharm
|
2013
|
0.82
|
|
77
|
Apolipoprotein E and alpha-1-antichymotrypsin genotypes do not predict time to psychosis in Alzheimer's disease.
|
J Geriatr Psychiatry Neurol
|
2002
|
0.82
|
|
78
|
Imaging tau deposits in vivo: progress in viewing more of the proteopathy picture.
|
Neuron
|
2013
|
0.81
|
|
79
|
Effects of lipophilicity on the affinity and nonspecific binding of iodinated benzothiazole derivatives.
|
J Mol Neurosci
|
2003
|
0.79
|
|
80
|
Biopsy support for the validity of Pittsburgh compound B positron emission tomography with a twist.
|
Arch Neurol
|
2008
|
0.79
|
|
81
|
Chrysamine G and its derivative reduce amyloid beta-induced neurotoxicity in mice.
|
Neurosci Lett
|
2002
|
0.78
|
|
82
|
Synthesis and evaluation of 2-(3'-iodo-4'-aminophenyl)-6-hydroxybenzothiazole for in vivo quantitation of amyloid deposits in Alzheimer's disease.
|
J Mol Neurosci
|
2002
|
0.78
|
|
83
|
Correction: Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group.
|
PLoS One
|
2016
|
0.75
|
|
84
|
Anomalous PiB enhancement in the superior sagittal and transverse venous sinuses.
|
Alzheimer Dis Assoc Disord
|
2012
|
0.75
|
|
85
|
Design, synthesis and structure-activity relationship of rhenium 2-arylbenzothiazoles as β-amyloid plaque binding agents.
|
Bioorg Med Chem Lett
|
2013
|
0.75
|